JHM 2C P H Dec 2019 current research text box

kaplin2  mikewangPrincipal Investigators: Dr. Adam Kaplin and Michael Wang, ScM

Research Institution: Johns Hopkins University School of Medicine 

Disease: Major depressive disorder

Research Description: Reports of depression and suicide have accelerated upward at unprecedented rates. Today, 41 million people are on antidepressants, a therapy with only a 33% success rate. Minimal insight into treatment-resistant depression exists, with few therapeutics outside of traditional treatment options. Recent research has shown success in treating depression with the anesthetic ketamine, which reactivates brain networks impaired by depression. Unfortunately, ketamine is impractical for addressing depression at large as it is highly intoxicating, government-restricted and requires intensive medical monitoring. Over-the-counter cough syrup has long been recognized to act both like ketamine and first-line antidepressants and might serve as a superior ketamine alternative with 50 years of safe and widespread use. This 15 patient clinical trial will ascertain the safety and efficacy of the active ingredient in cough syrup, dextromethorphan (DXM), in treating major depressive disorder.

CWR funding role: Primary funder

CWR funding partner: The Kahlert Foundation


Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at admin@cureswithinreach.org with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Tuesday the 7th. Copyright 2018 Cures Within Reach.